Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Align TechnologyXTER:AFW 89 3-Year EBITDA Growth Rate is 4.50% as of Jun. 2026, which is 78% below its 10-year median of 20.10. GuruFocus rates XTER:AFW with a GF Score™ of 89/100 and a GF Value™ of €205.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Align Technology ranks worse than 57.54% on this metric.
During the past 12 months, Align Technology's average EBITDA Per Share Growth Rate was 17.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Align Technology was 45.20% per year. The lowest was -7.20% per year. And the median was 20.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Align Technology 3-Year EBITDA Growth Rate Related Terms
XTER:AFW vs BAX, SOLV, COO: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Align Technology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Align Technology 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Align Technology's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.50% mean?
Align Technology (XTER:AFW) has a 3-Year EBITDA Growth Rate of 4.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Align Technology and its competitors. This is 78% below median its historical median of 20.10. According to the industry distribution chart, Align Technology ranks #397 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 57.5%.
Is Align Technology's 3-Year EBITDA Growth Rate too high?
Align Technology's current 3-Year EBITDA Growth Rate of 4.50% is 78% below median its 10-year median of 20.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.35. Align Technology's value of 4.50% is 46.1% below this industry median. Based on the distribution chart, Align Technology ranks #397 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Align Technology has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Align Technology's 3-Year EBITDA Growth Rate compare to BAX and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Align Technology ranks #397 out of 690 companies for 3-Year EBITDA Growth Rate. This places Align Technology in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.35. Align Technology's value of 4.50% is 46.1% below this benchmark. While the company's 10-year median is 20.10 vs. the industry median of 8.35, Align Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.35, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Align Technology's current 3-Year EBITDA Growth Rate of 4.50% is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Align Technology and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Align Technology's current 3-Year EBITDA Growth Rate is 4.50%, which is 78% below median its own 10-year median of 20.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Align Technology stock overvalued right now?
Based on GuruFocus' analysis, Align Technology (XTER:AFW) is currently considered Modestly Undervalued. The stock's GF Value™ is €205.13, compared to a current price of €153.60 — trading 25.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.50%, which is 78% below median its 10-year median of 20.10 and 46.1% below the Medical Devices & Instruments industry median of 8.35. Align Technology's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Align Technology (XTER:AFW), the current 3-Year EBITDA Growth Rate is 4.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Align Technology (XTER:AFW) Overvalued in 2026?
Based on GuruFocus' analysis, Align Technology stock appears to be undervalued.
The current stock price of €153.60 is trading 25.1% below its estimated GF Value™ of €205.13.
GuruFocus considers Align Technology to be Modestly Undervalued.
Key valuation signals for XTER:AFW:
3-Year EBITDA Growth Rate: 4.50% (78% below median its 10-year median of 20.10)
GF Value™: €205.13 vs. price of €153.60 (25.1% below fair value)
Industry Position: 46.1% below the Medical Devices & Instruments median (#397 of 690)
No single metric tells the full story. See the XTER:AFW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
89GF Score
Get the complete analysis for XTER:AFW
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AFW has been successfully added to your 
